NCT06827002Active, not recruitingPhase 1/2
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
Obesity is a global health crisis affecting over 2.3 billion individuals worldwide. This prospective study aims to evaluate the comparative effects of standardised Cissus quadrangularis extract (CQE) and Dichrostachys glomerata extract (DGE) on obesity-related parameters, focusing on their impact on glucagon-like peptide-1 (GLP-1) levels and dipeptidyl peptidase-4 (DPP-4) enzyme activity in obese subjects. Parameters such as GLP-1 levels, DPP-4 activity, food intake, satiety, body weight, blood lipids, fasting blood glucose, and visceral fat mass will be measured at baseline and various intervals. In our previous pre-clinical trial involving 18 adult male Wistar rats (150-200 g), randomly divided into three groups: a control group fed a normal diet, and two treatment groups receiving DGE (400 mg/kg) or CQE (300 mg/kg) alongside a normal diet, the results demonstrated that both DGE and CQE significantly increased GLP-1 levels and inhibited DPP-4 activity compared to the control group. These effects were associated with reduced food intake, body weight, and fasting blood glucose levels. Additionally, both extracts positively modified blood lipid profiles, with significant changes in HDL, LDL, and triglyceride levels. The findings suggest that DGE and CQE exert their anti-obesity effects through mechanisms involving GLP-1 enhancement and DPP-4 inhibition, offering potential therapeutic pathways for weight management and metabolic health. This prospective study aims to provide clinical evidence supporting the use of these plant extracts in addressing obesity and its related complications.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 248 (actual)
- First submitted
- 29 Jan 2025
- Start date
- 29 Mar 2023
- Primary completion date
- 23 Feb 2026
- Lead sponsor
- University of Yaounde 1
- Diseases
- Obesity
- NCT number
- NCT06827002
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 248
- From 29 Mar 2023 to the primary completion date, 23 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any medication or natural health product that might affect the parameters of interest in this study
Other illness
- Diabetes mellitus requiring daily insulin management
- Active infection
- Systemic diseases, including HIV/AIDS, Active hepatitis, Clinical signs of active malignancy within the past 5 years
Age
- Participants younger than 18 years or older than 65 years
Other
- Participants not available for the study period
- Morbid obesity (BMI \> 34.9 kg/m²)
- Pregnancy or breastfeeding
Who the study is looking for
- Healthy males and non-pregnant/non-lactating females
- Participants aged 18 to 65 years old
- Participants with BMI between 25 and 34 kg/m²
- Participants willing to comply with the study protocol
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Yaounde 1 Coordinator of this site? Confirm its status | Yaoundé | Cameroon | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.